A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Inclusion Criteria:

- Provision of signed, written, and dated informed consent prior to any study-specific
procedures Male and nonfertile female healthy subjects, aged 18 to 55 years at the
time of consent

- Body weight ≥50 to ≤100 kg and body mass index (BMI) ≥19 to ≤30 kg/m2

- Clinically normal findings on physical examination in relation to age, as judged by
the Investigator

- Male healthy subjects must be willing to use barrier contraception, ie, condoms, even
if their partners are post-menopausal, surgically sterile, or using accepted
contraceptive methods, from the first day of dosing until 3 months after the last
dose of investigational product (IP)

Exclusion Criteria:

- Participation in any prior study of AZD3293

- History of any clinically significant disease or disorder which, in the opinion of
the Investigator, may put the subject at risk because of participation in the study,
may influence the results, or may limit the subject's ability to participate in the
study

- History or presence of gastrointestinal, hepatic or renal disease or any other
condition known to interfere with absorption, distribution, metabolism or excretion
of drugs

- History of previous or ongoing psychiatric disease/condition including psychosis,
affective disorder, anxiety disorder, borderline state and personality disorder
according to the criteria in the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM IV), as assessed by the Mini-International
Neuropsychiatric Interview (MINI)